KBIO Labs Swings to Q1 Net Profit of 2.3B Won, Corrects Related Party Classification
Consolidated revenue 15.9B won (vs 20.5B), operating loss 0.8B, net profit 2.3B (vs 0.05B) - Parent revenue 9.5B (vs 7.0B), net profit 0.94B (vs loss 0.23B) - Correction filing reflecting reclassification of related parties (Fantagio to other, exclusion of Kyungnam Pharm, etc.) - Total equity 104.5B, deficit 51.6B, treasury shares 217,506 - Net profit improved due to financial asset valuation gains (1.36B), but core business profit declined
KOSDAQ Filing Information
Filing: [Correction of Description] Quarterly Report (2026.03)